Food safety and quality: details

兽药

Enrofloxacin

功能分类

Antimicrobial agent

最新评价

1997

食品添加剂和污染物联合专家委员会

每日允许摄入量

0-2 µg/kg bw

每日允许摄入量状况

Full

残留量专题文集

41-7-enrofloxacin.pdf

残留标示物

建议的最高残留限量

其他说明

The Committee postponed, at its 48th meeting, the evaluation of the residue data due to the late submission of important additional data.

评价概要

Based on the temporary ADI of 0-0.6 µg/kg for enrofloxacin established by the Committee, the permitted daily intake of parent drug and/or it sequivalents is 36 µg for a 60-kg person. In reaching its decision on the MRLs, the Committee considered thefollowing factors:
- The temporary ADI was based on a microbiological end-point.
- The quantification limits of the analytical methods (10 µg/kg for enrofloxacin and ciprofloxacin in tissues and 5 µg/kg in milk).
- The marker residue for tissues is the sum of the enrofloxacin and ciprofloxacin residues. Ciprofloxacin is the marker residue for bovinemilk.
- Neither the ratio of marker residue to total residues nor the percentage of total residues associated with antimicrobial activity was known.
- Since enrofloxacin and ciprofloxacin account for only 20% of total residues in pig liver, the intake of antimicrobially active residues could be up to five times the concentration of the marker residues.
The Committee noted that even if the MRLs were based on the limits of quantification of the most sensitive analytical methods multiplied by a factor of 2, the intake of marker residues from muscle, liver, kidney, fat, milk and eggs would be 39 µg, which is close to the maximum ADI of 36 µg. However, the Committee noted that the hypothetical MRLs based on the limits of quantification of the analytical method would not take intoaccount any antimicrobial activity of the significant fraction (up to 80%) forming the remaining residues. It therefore concluded that it was not possible to allocate MRLs to enrofloxacin.
TRS 855

网络版“:食品和家畜中的一部分兽药残留”